Jhajjar
Jhajjar
Jhajjar, Haryana, India7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Not applicable | 2026-09-24 | NCT07565987 | |
| The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas | Deglutition Disorders, Digestive System Diseases, Head and Neck Neoplasms, Neoplasms by Site, Pharyngeal Diseases, digestive system disorder, esophageal disorder, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2026-09-11 | NCT05187091 | |
| Global Trial in APG2575 for Patients With CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 3 | 2026-06-18 | NCT06104566 | |
| Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-05-07 | NCT07573956 | |
| A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's | Head and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-05-06 | NCT07528495 | |
| Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-01-13 | NCT06755450 | |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervical squamous cell carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal cancer, esophageal disorder, esophageal squamous cell carcinoma, estrogen-receptor positive breast cancer, female reproductive system disorder, female reproductive system neoplasm, gastroesophageal cancer, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma, primitive neuroectodermal tumor, prostate cancer, prostate disorder, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Active, not recruiting | Phase 1 | 2025-11-28 | NCT03983954 |